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ABSTRACT
Background and aims: Docetaxel (DTX) modestly increases patient survival 
of metastatic castration-resistant prostate cancer (mCRPC) due to insurgence of 
pharmacological resistance. Deregulation of Chromosome Region Maintenance (CRM-1)/ 
exportin-1 (XPO-1)-mediated nuclear export may play a crucial role in this phenomenon.
Material and methods: Here, we evaluated the effects of two Selective Inhibitor 
of Nuclear Export (SINE) compounds, selinexor (KPT-330) and KPT-251, in association 
with DTX by using 22rv1, PC3 and DU145 cell lines with their. DTX resistant derivatives.
Results and conclusions: We show that DTX resistance may involve overexpression 
of β-III tubulin (TUBB3) and P-glycoprotein as well as increased cytoplasmic 
accumulation of Foxo3a. Increased levels of XPO-1 were also observed in DTX resistant 
cells suggesting that SINE compounds may modulate DTX effectiveness in sensitive 
cells as well as restore the sensitivity to DTX in resistant ones. Pretreatment with SINE 
compounds, indeed, sensitized to DTX through increased tumor shrinkage and apoptosis 
by preventing DTX-induced cell cycle arrest. Basally SINE compounds induce FOXO3a 
activation and nuclear accumulation increasing the expression of FOXO-responsive 
genes including p21, p27 and Bim causing cell cycle arrest. SINE compounds-catenin and 
survivin supporting apoptosis. βdown-regulated Cyclin D1, c-myc, Nuclear sequestration 
of p-Foxo3a was able to reduce ABCB1 and TUBB3 H2AX levels, prolonged γ expression. 
Selinexor treatment increased DTX-mediated double strand breaks (DSB), and reduced 
the levels of DNA repairing proteins including DNA PKc and Topo2A. Our results provide 
supportive evidence for the therapeutic use of SINE compounds in combination with DTX 
suggesting their clinical use in mCRPC patients.
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INTRODUCTION
Prostate cancer (PCa) is the second leading cause 
of cancer-related death in males in industrialized western 
countries and represents a growing problem worldwide 
[1]. Hormone refractory/castration resistant PCa (CRPC) 
usually develops after an initially therapeutically 
efficacious treatment with anti-hormonal compounds [2]. 
CRPC is also associated with resistance to conventional 
chemotherapies. Docetaxel (DTX), a first line treatment 
for CRPC, confers survival advantages of approximately 
2 months for patients [3, 4] with low overall survival 
benefit. Indeed, most patients with CRPC relapse and 
become resistant to DTX therapy [4–7]. Despite the high 
prevalence of DTX-refractory disease, little is known 
about the tumor biology of the DTX-resistant residual 
tumor cells compared with primary tumor cells. Gene 
expression profiling of androgen independent prostate 
cancer cells demonstrates complex mechanisms mediating 
resistance to DTX [10]. In addition, ABC drug transporter 
family proteins [8] and clusterin [7, 9], have been proposed 
to play a role in resistance. Accumulating evidence 
suggests that more aggressive disease develops after 
DTX-resistance [11, 12] with recruitment and activation 
of cancer stem [13, 14]. In breast cancer, it was recently 
shown that residual cancer cells increased mammosphere 
formation efficacy when compared to primary cancers [9]. 
Thus, the tumorigenic potential of residual/DTX-resistant 
(DTXR) cancer cells may be enhanced if the cancer cells 
were not eradicated by chemotherapy.
It has been previously observed that tumorigenic 
potential was increased in DTXR residual prostate 
cancer cell lines when compared to parental cells 
[15]. Tumorigenic potential in DTXR PCa could be 
conferred by oncogenic c-Myc, which was stabilized 
by constitutively activated ERK1/2 in resistant cells. 
Constitutively activated ERK1/2 was maintained by 
CXCR4, which was also upregulated in resistant cells. It 
is now commonly accepted that constitutive activation of 
the CXCR4, ERK1/2, and c-Myc signaling loop plays a 
major role in prostate tumorigenesis [15, 16].
The nucleo-cytoplasmic shuttling of proteins 
and RNAs is a dynamic process that is regulated by the 
exportin family of proteins. Exportin-1 (XPO-1), also 
known as chromosomal region maintenance 1 (CRM1), 
shuttles about 220 proteins from the nucleus to the 
cytoplasm [17, 18] and is the sole nuclear exporter of 
several tumor suppressor (TSP) and growth regulatory 
(GRP) proteins, such as p53 and p73 [19, 20], p21 [21], 
survivin [22, 23], cyclin D1 [23, 24], Rb1 [25], apc 
[26], bcr-abl [27], FOXO [28], p27 [29] and STAT3 
[30]. Physiologically, export of these proteins prevents 
unnecessary activity in the absence of DNA injury 
and other oncogenic activities [31–33]. In tumor cells, 
however, the export of these proteins inhibits their activity 
thus promoting tumorigenesis. Many hematologic and 
solid tumors have elevated XPO-1 levels [34–37] with a 
strong correlation between increased XPO-1 expression 
and poor prognosis, as demonstrated in osteosarcoma [38], 
pancreatic [39], lung [35] and ovarian cancers [34].
PI3K/Akt/mTOR/GSK3β signaling has been shown 
to increase XPO-1 dependent nuclear export of TSPs, 
whereas its inhibition [40–43] as well as that of XPO-1 
[22, 23] reduces this turnover/recycling. In contrast, PTEN 
is known to antagonize oncogenic PI3K/Akt signaling. 
The expression of PTEN, a cargo of XPO-1, is repressed 
or lost in PCa [45, 46]. It has been also described that the 
shuttling of cyclin D1 (CCND1 [23], responsible for the 
progression of cell cycle and regulating the G1/S-phase 
transition of proliferating cells [44]), from the nucleus to 
the cytoplasm is regulated by XPO1. Inhibition of XPO-
1 and thus the nuclear export of cyclin D1 may activate 
caspase activity and apoptotic machinery. Similarly, 
surviving, when localized in nucleus, is mainly involved 
in spindle monitoring at mitosis, whereas cytoplasmic/
mitochondrial survivin counteracts pro-apoptotic signals 
by preventing caspase-9 and caspase-3 activation, thus 
XPO-1 inhibition and the nuclear enrichment of survivin 
would inhibit the anti-apoptotic activity of survivin [22].
A recently developed series of slowly reversible 
orally available Selective Inhibitor of Nuclear Export 
(SINE) compounds bind to XPO-1 and inhibit XPO-
1 mediated nuclear export [for review see 40]. SINE 
compounds are actively being evaluated in human [46, 
47] and animal clinical trials [48, 49]. In our study, we 
investigated whether two SINE molecules (KPT-251 
and KPT-330/ selinexor) would also be effective against 
CRPC cells in combination with DTX. We hypothesize 
that elevated XPO-1 expression is associated with DTXR, 
as described in a previous report [50], and that the 
inhibition of this cargo protein may sensitize to DTX in 
both naive and resistant clones. Here, we show that XPO-
1 inhibition using KPT-251 and selinexor enhances the 
sensitivity to DTX and conclude that the XPO-1 mediated 
shuttling of nuclear proteins might play an important role 
in inducing resistance to chemotherapeutic drugs in PCa 
cells. Together this data suggests that targeting XPO-1 
might be a promising strategy for enhancing sensitivity to 
chemotherapy in CRPC.
RESULTS
Effects of docetaxel in DTX sensitive PC3, 22rv1 
and DU145 cell lines
First, we analyzed the effects of DTX on PC3, 
DU145 and 22rv1 cell lines. In Figure 1A we show 
the plate image representation of crystal violet stained 
PC3, 22rv1 and DU145 cells cultured in 24 well/plates 
with different doses of DTX (0-20 nM). Proliferation of 
these cells was inhibited by DTX (Figure 1B) with IC50 
values of 7.20 nM in p53 null PC3 cells, 1.26 nM in p53 
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wild type 22rv1 cells, and 16.17 nM PTEN mutant and 
inactive DU145 cells. It is well known that DTX is able 
to induce replication stress promoting DSBs and leading 
to activation of multiple molecular pathways regulating 
DNA repair, including ATM-Chk2-p53 (22rv1 cell 
line), ATR-Chk1 (PC3 and DU145 cell lines) and PARP 
signaling. In addition we observed that DTX increased 
the levels γH2AX and phosphorylation of Chk1/2, 
which are indicative of DNA damage and kinase activity, 
respectively. In Figure 1C and 1E we show western 
blotting evaluation on molecular arrangement induced 
by 10 nM in p53 mutated PC3 cells (1C) and 1 nM in 
p53 wild type 22rv1 cells (1E). DTX doses close to the 
IC50 values were chosen for both cell lines. The levels of 
γH2AX, Chk1 and Chk2 were normalized using histone 
H3, whereas phosphorylated forms of Chk1 (p-Ser345) 
and Chk2 (p-Tyr68) were normalized to total expression 
of Chk1 and Chk2, respectively. From a first analysis of 
western blotting of PC3 and 22rv1 cells treated with DTX, 
γH2AX reached maximal levels at 24 hours then dropped 
to reach sub-baseline values. In 22rv1 cells (Figure 1F) 
the increase of γH2AX was more gradual without a clear 
return to basal values. This data suggests that 22rv1 
cells were actively trying to repair DNA but could not. 
As a result, they again activated DDR, as evidenced by 
high γH2AX levels. PC3 cells seem to have completed, 
instead, the DNA-repair and could resume their cell 
proliferation after an initial cytostasis. The levels of Chk1 
and Chk2 were significantly reduced in the time indicating 
possible shuttling in the cytoplasm and degradation. The 
reduction of Chk1 levels was higher when compared 
to those observed for Chk2. The normalized levels of 
the phosphorylated nuclear isoforms of Chk1 and Chk2 
(Figure 1D, 1F) were increased in the time especially in 
22rv1 cells. Chk1 and Chk2 activation was consistent 
with that observed for γΗ2AX. The levels p-(ser345)Chk1 
increased in PC3 and 22rv1 (Figure 1D, 1F) following the 
increment of γΗ2Ax levels and were maximal at 48 hours 
although γΗ2Ax expression levels dropped in PC3 cells 
(Figure 1D). Levels of p-Chk2(Tyr68) increased both in 
PC3 and 22rv1 cells. Chk1 and Chk2 activation levels 
are different in PC3 and 22rv1cells and this suggests 
differences in the DTX-mediated cell apoptosis (Figure 
1G) and caspase 3 activation (Figure 1H). In PC3 cells 
(in the absence of p53) DNA damage signals a replicative 
block in S and G2/M cell cycle phase. In 22rv1 (in the 
presence of p53) a further replicative block may be 
observed in the passage from G1 to S. In the Figure 1G 
we show FACS determinations demonstrating a bigger 
G2/M cell peak, corresponding to a cell cycle arrest in 
this phase, in PC3 cells whereas a reduction of this peak 
observed in 22rv1 cells, was indicative of G0/G1 cell cycle 
arrest and this was in agreement with several literature 
data. DU145 cells, with mutant and not functional p53, 
follow the trend of PC3 cells also if the G2/M peak in 
the administration of the IC50 dose of DTX seemed to 
be reduced compared to that observed at IC20 dose. The 
block of G2/M was associated also with increased subG1 
apoptotic cells ranged between 25% (PC3 cells) and 67% 
(22rv1 cells). In addition we demonstrate a critical role of 
Chk1 in the protection to cell death. The addition of 50 nM 
Chk1 inhibitor CCT244747 (Figure 1I), indeed, breaching 
down Chk1 activity allows to start and thus accelerate the 
program of cell death.
Next, we confirmed that DTX resistant cell 
derivatives were effectively resistant to this compound. In 
Figure 2A we show plate image representations of crystal 
violet stained DU145DTXR, 22rv1DTXR and PC3DTXR 
cells grown in 24 well plates cultured with different doses 
of DTX (0-500 nM) and having significant higher IC50 
values (Figure 2B) to those observed for DTXS cell strains 
reaching 225 nM (PCE3DTXR), 44 nM (22rv1DTRX) 
and 78 nM (DU145DTXR). Also in DTXR cells, DTX 
at IC50 values for each cell lines induced DNA damage 
response (DDR) characterized by γH2AX phosphorylation 
and Chk1/2 kinase activation (Figure 2C in PC3DTXR 
and Figure 2E in 22rv1DTXR cells). Our data shows that 
γH2AX reached maximal levels at 8-16 hours both in 
PC3DTXR (Figure 2C, 2D) and 22rv1DTXR (Figure 2E, 
2F) cells, then returned to baseline values at 48 and 72 
hours suggesting that DNA damage was repaired. Chk1 
kinase activation (p-Ser345) levels increased in a time-
dependent manner in 22rv1 cells (Figure 2E, 2F) whereas 
reached maximal levels up to 16 hours in PC3 Figure 2C, 
2D), then went down and remained at sub-baseline values. 
The levels of p-Tyr68 Chk2 remained elevated until the 8 
hour time point (Figure 2D, 2F), then decreased at the 16 
hour time point and reached maximum values at 48 and 
72 hours. In both cell lines the levels of Chk1 and Chk2 
were maintained high and the levels of γH2AX decreased, 
suggesting that DNA was not repaired. As expected, 
caspase-3 activity and apoptosis were not observed (Figure 
2G) as the cells are DTXR. The protective role of Chk1 
was further tested by using 50 nM CCT244747 (Figure 
2H) showing synergistic effects in association with DTX.
Next, we compared some molecular profiles in 
parental and resistant cell lines. Consistent with previous 
reports [57-59], we show that that DTXR cells had 
significant higher levels of βIII tubulin, Foxo3a and 
ABCB1 when compared to parental ones (Figure 3A, 
3C). The expression of HDAC-6, which interacts with 
and deacetylates α-tubulin and microtubules in vivo, was 
also increased in resistant cells. The expression levels of 
α-tubulin were significantly lower in resistant cells when 
compared to parental ones (Figure 3A). 22rv1 DTXR cells 
showed no modulation of p-FOXO3a (S253), PC3 DTXR 
cells showed a slight reduction expression whereas DU145 
cells showed a significant strong reduction of p-FOXO3a 
(S253) as shown in Figure 3A, 3C). DTX resistant cells 
showed also higher levels of p-AktT308 and p-AktS473. 
XPO-1 expression levels were higher in the cytoplasm 
when compared to nucleus of PCa cells and this difference 
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Figure 1: Effects of docetaxel (DTX) in DTX sensitive (DTXS) PC3, 22rv1 and DU145 cell lines. (A) Plate image 
representation of crystal violet stained PC3, 22rv1 and DU145 cells cultured in 24 well/plates with different doses of DTX (0-20 nM). (B) 
Proliferation curve generated with Graftit software for PC3 (IC50=7.21 nM), 22rv1 (IC50=1.26 nM) and for DU145 cells (IC50=15.17 nM). 
(C) DTX (10.0 nM) induces time-dependent DNA damage response (DDR) characterized by γ-H2AX phosphorylation and Chk1/2 kinase 
activation in PC3 cells. (D) The levels of γH2AX, Chk1 and Chk2 were normalized by using H3 histone as housekeeping nuclear protein, 
whereas those of phosphorylated forms of Chk1 (p-Ser345) and Chk2 (p-Tyr68) with total expression of Chk1 and chl2, respectively. 
Normalizing expression levels were plotted in the time for PC3 cells. (E) DTX (1.0 nM) induces time-dependent DNA damage response 
(DDR) characterized by γ-H2AX phosphorylation and Chk1/2 kinase activation in 22rv1 cells. (F) The levels of γH2AX, Chk1 and Chk2 
were normalized by using H3 histone as housekeeping nuclear protein, whereas those of phosphorylated forms of Chk1 (p-Ser345) and 
Chk2 (p-Tyr68) with total expression of Chk1 and chl2, respectively. Normalizing expression levels were plotted in the time for 22rv1 cells. 
(G) FACS analyses for apoptotic rate in CTRL and DTX treated cells at IC20 and IC50 values. IC20 values were 0.5 nM, 5.8 nM and 10 
nM for 22rv1, PC3 and DU145, respectively (H) caspase 3 activation /cleavage. (I) Addition of 50 nM Chk1 inhibitor CCT244747 start 
and accelerate the program of cell death in PC3, 22rv1 and DU145 cells. Each lane of western blots was loaded with 100 μg of proteins. 
Graphical data derived from three different western blot analysis performed on different cell extracts. Data presented as mean ±Error 
Standard (ES). Data for γH2AX are statistically significant at all considered times whereas p(SER235)-Chk1 and p(Tyr68)-Chk2 levels 
were significant starting from 16 and 24 hour, respectively (p<0.001).
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was increased in DTXR respect to DTX sensitive (DTXS) 
cells. This was in agreement with our previous data 
showing that more aggressive PCa cells showed higher 
XPO1 levels and cytoplasmatic localization [23].
In addition, we demonstrate that treatment with DTX 
was able to modulate the nuclear and cytoplasmatic levels of 
XPO1 (Figure 3B). In Figure 4A we show that administration 
of 20 nM DTX stimulated, in DTXS PC3 cells, an initial 
nuclear translocation of XPO1 at 24-48 hours (Figure 4A, 
4B) and a late reduced nuclear expression. Similarly, DTXR 
PC3 cells treated with 100 nM DTX increased the levels of 
nuclear XPO1 at 24 hours which was reduced at very low 
extent at 72 and 96 hours (Figure 4B). A number of studies 
demonstrated a role for FOXO3a in tumor progression 
by promoting invasive migration of cancer cells [58, 59]. 
For example, FOXO3a promotes metastasis in the context 
Figure 2: Effects of docetaxel (DTX) in DTX resistant (DTXR) PC3, 22rv1 and DU145 cell lines. (A) Plate image 
representation of crystal violet stained PC3DTXR, 22rv1DTXR and DU145DTXR cells cultured in 24 well/plates with different doses of 
DTX (0-500 nM). (B) Proliferation curve generated with Graftit software for PC3DTXR (IC50=225.39 nM), 22rv1 (IC50=43.85 nM) and 
for DU145 cells (IC50=78.40 nM). (C) DTX (200 nM) induces time-dependent DNA damage response (DDR) characterized by γ-H2AX 
phosphorylation and Chk1/2 kinase activation in PC3DTXR cells. (D) The levels of γH2AX, Chk1 and Chk2 were normalized by using 
H3 histone as housekeeping nuclear protein, whereas those of phosphorylated forms of Chk1 (p-Ser345) and Chk2 (p-Tyr68) with total 
expression of Chk1 and chl2, respectively. Normalizing expression levels were plotted in the time for PC3DTXR cells. (E) DTX (40 
nM) induces time-dependent DNA damage response (DDR) characterized by γ-H2AX phosphorylation and Chk1/2 kinase activation 
in 22rv1DTXR cells. (F) The levels of γH2AX, Chk1 and Chk2 were normalized by using H3 histone as housekeeping nuclear protein, 
whereas those of phosphorylated forms of Chk1 (p-Ser345) and Chk2 (p-Tyr68) with total expression of Chk1 and chl2, respectively. 
Normalizing expression levels were plotted in the time for 22rv1DTXR cells. (G) caspase 3 activation /cleavage. (H) Addition of 50 nM 
Chk1 inhibitor CCT244747 start and accelerate the program of cell death in PC3DTXR, 22rv1DTXR and DU145DTXR cells. Each lane of 
western blots was loaded with 100 μg of proteins. Graphical data derived from three different western blot analysis performed on different 
cell extracts. Data presented as mean ±Error Standard (ES). In PC3DTXR cells, data for γH2AX are statistically significant starting to 
2 hours and until 24 hours; p(SER235)-Chk1 was statistically significant at 8 hour and at 72 hour whereas only p(Tyr68)-Chk2 levels 
significantly followed a time-dependent increase (p<0.001). In 22rv1DTXR γH2AX, p(Ser235)-Chk1 and p(Tyr68)-Chk2 levels followed 
a statistically significant time-dependent increase (p<0.001).
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of nucleus accumulation of β-catenin [59]. The finding 
suggests that nuclear FOXO3a and β-catenin may synergize 
to promote transcription of genes that are involved in 
scattering and metastasis. So, we first compared the nuclear 
and cytoplasmatic levels of β-catenin, c-myc and cyclin 
D1 (Figure 4C) and next the molecular re-arrangement 
induced by DTX on GSK3β/Foxo3a/β-catenin pathways 
both in DTXS and DTXR PC3 cells. We found that resistant 
strains showed high levels of oncogenic protein involved 
in the Foxo3a/β–catenin pathways. For example, cyclin D1 
was equally distributed between cytoplasm and nucleus in 
both sensitive and resistant strains and was associated to 
elevated levels of β-catenin. Similarly c-myc was induced 
especially in the nuclear microenvironment and reduced in 
the cytoplasm of resistant DU145 cells.
After normalizations first versus total Foxo3a 
(for p-Foxo3a) or Histone H3 (for β-catenin, c-myc and 
cyclin D1) and next versus Time 0 (T0) we demonstrated 
that in the PC3DTXS cell strain, DTX administration 
significantly reduced the nuclear levels of p-Foxo3a 
(Figure 4D, 4E) up to 48 hours. Subsequently they 
went up to reach the maximum levels at 72 hours. In 
Figure 3: (A) Differences in molecular arrangements on DTX sensitive and resistant CRPC cell lines. (B) Nuclear and cytoplasmic 
expression of XPO1 in sensitive and resistant CRPC cell lines. Western blot for nuclear extracts were also blotted with anti β-actin antibody 
to verify the presence of cytosolic proteins. (B) Foxo3a, p-Foxo3a, ABCB1 and βIII tubulin levels in DTX resistant CRPC cells expressed 
as fold increase (C) vs DTX sensitive cells. Each lane was loaded with 100 mg of proteins. Graphs were made analyzing three different 
western blots. * p<0.001.
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Figure 4: (A) Effects of 10 nM DTX in DTXS cells (time-dependent trend) on XPO1 expression in nuclear, cytoplasmic and total cell extracts. 
(B) Differences in the modulation of XPO1 expression, normalized vs Histone H3, during DTX administration in DTXS (DTX=10 nM) and 
DTXR (DTX=200 nM) PC3 cell strains. (C) Nuclear and cytoplasmatic Expression of β-catenin and its related targets (c-myc and cyclin D1) in 
DTX resistant and sensitive CRPC cells. (D) Modulation of nuclear and cytoplasmatic expression of GSK3β/Foxo3a/β-catenin and related target 
proteins (c-myc and cyclin D1) in DTXS and DTXR PC3 cell strains treated with 10 and 200 nM DTX, respectively. Immunoblots for p-Foxo3a, 
β-catenin, c-myc and cyclin D1 were normalized first versus the levels of Histone H3 and next on the levels at Time 0 (T0). Three western blots 
were analyzed and data expressed as mean of fold increases versus T0 ± Standard Error (SE). (E) Modulation of nuclear expression levels of 
p-Foxo3a in PC3DTXS and PC3DTXR cells; (F) modulation of nuclear expression levels of β-catenin in PC3DTXS and PC3DTXR cells; (G) 
modulation of nuclear expression levels of c-myc in PC3DTXS and PC3DTXR cells; (H) modulation of nuclear expression levels of cyclin D1 
in PC3DTXS and PC3DTXR cells. (I) Western blot and zymographic evaluation of antiproliferative/cell cycle dependent (p21 and p27), EMT 
(Survivin, VEGF-A, N-cadherin and metalloproteinases) and Epithelial (E-cadherin) related targets.
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the PC3DTXR cell strain, instead, the nuclear p-Foxo3a 
levels grew in a time-dependent manner (Figure 4D, 
4E). Parallely, cytoplasmatic expression of Foxo3a was 
progressively reduced in the time (Figure 4D) in both cell 
strains.
Several studies demonstrated a role for FOXO3a 
in tumor progression through the promotion of invasive 
migration of cancer cells [58, 59]. An important target of 
Foxo3a in the activation of this pathway is the β-catenin 
which undergoes continuous nuclear to cytoplasmic shuttling 
and vice versa, which regulates its function [59]. So, Foxo3a 
and β-catenin could synergize to promote transcription of 
genes that are involved in scattering and metastasis. Next 
we verified the nuclear and cytoplasmatic levels of β-catenin 
as well as the expression of some downstream targets of 
β-catenin (indicators of activity) such as c-myc, cyclin D1, 
cytokeratin 18, E-cadherin, N-cadherin and MMP-9. As 
expected higher β-catenin levels were found in PC3 DTXR 
cell strain when compared to PC3DTXS ones (Figure 4F) 
suggesting that β-catenin expression could be associated 
with drug resistance to DTX. So we verified if β-catenin 
levels were modified by DTX treatment in both cell strains. 
We observed that the levels of β-catenin were significantly 
reduced in the nucleus of both DTX sensitive or resistant 
treated PC3 cells with similar degree (Figure 4D, 4F). The 
analyses of the cytoplasmatic levels of this protein showed an 
increased proteolysis observed in PC3 DTXS cells at 72 and 
96 hours of treatment with DTX (Figure 4D).
Figure 5: Synergy head maps for Combination Index (CI), calculated by Chou-Talay method. (A) PC3 synergy map 
calculated for selinexor and DTX co-treatment. (B) DU145 synergy map calculated for selinexor and DTX co-treatment. (C) Reduction 
of DTX sensitivity (IC50) calculated for PC3 cultured with selinexor and KPT-251 at IC20 values of 100 nM and 78 nM, respectively. 
(D) Reduction of DTX sensitivity (IC50) calculated for 22rv1 cultured with selinexor and KPT-251 at IC20 values of 75 nM and 56 nM, 
respectively. (E) Reduction of DTX sensitivity (IC50) calculated for DU145 cultured with selinexor and KPT-251 at IC20 values of 50 nM 
and 58 nM, respectively. (F) Reduction of DTX sensitivity (IC50) calculated for PC3DTXR cultured with selinexor and KPT-251 at IC20 
values of 120 nM and 85 nM, respectively. (G) Reduction of DTX sensitivity (IC50) calculated for 22rv1DTXR cultured with selinexor and 
KPT-251 at IC20 values of 90 nM and 75 nM, respectively. (H) Reduction of DTX sensitivity (IC50) calculated for DU145DTXR cultured 
with selinexor and KPT-251 at IC20 values of 135 nM and 92 nM, respectively. Synergy is showed in the red boxes, additivity in yellow 
boxes and competition in green boxes. Black arrows represent the IC50 values for both compounds.
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The expression of c-myc was significantly reduced 
in DTXS PC3 cells both in the nucleus and in the 
cytoplasm (Figure 4D). The comparison between DTX 
sensitive and resistant cells treated with DTX shows that 
c-myc undergoes a reduction of about 50% in resistant 
cells whereas that observed in sensitive cells was much 
more of 150% (Figure 4G). The levels of GSK3β were 
not significantly modified in DTXS PC3 cells whereas 
in DTXR PCX3 cells p-GSK3β levels progressively 
decreased after an early induction due probably to 
modifications in Akt activity. Nuclear accumulation was, 
instead, observed for Cyclin D1 (Figure 4H), a protein that 
must exit the nucleus in the transition from G2/M to G0/
G1 of cell cycle. This justify further that PC3 are arrested 
in the G2/M cell cycle phase.
Expression of VEGF-A as well as N-cadherin, a 
marker for Epithelial-Mesenchymal Transition (EMT) 
are related to a β-catenin nuclear activity. So we verified 
if DTX sensitivity/resistance was associated to EMT 
phenotype. It has been well known that DTXR cells 
express higher levels of N-cadherin of DTXS cells. 
Similarly, VEGF-A secretion was higher in DTXR when 
compare to DTXS cells. Conversely, the levels of epithelial 
markers such as cytokeratin 18 (K18) or E-cadherin were 
significantly reduced in DTXR. Short-term administration 
of DTX was able to down-regulate N-cadherin and VEGF 
levels in DTXS cells whereas no changes were found in 
DTXR (Figure 4I) No significant modulation by DTX 
administration was found in zymographic analyses for 
MMP2 whereas MMP9 appear to be significantly down-
regulated. Cell cycle dependent p21 and p27 proteins was 
upregulated indicating cell cycle arrest. The levels of Erk 
were up-regulated in DTXR cells whereas a significant 
down-modulation was observed in DTXS cells and this 
was in agreement with the higher effects of DTX in 
DTXS when compared to those observed in DTXR cells. 
DTXR cells result also protected by different intracellular 
signaling involving Akt and MAPK.
XPO1 inhibition increases the sensitivity to DTX 
in PC3, DU145 and 22rv1 DTX sensitive cells 
and sensitizes DTXR PC3, 22rv1 and DU145 
cells to DTX in vitro
The combination of selinexor with DTX 
demonstrated a significant reduction of tumor cell viability 
as evidenced by a dose-dependent chemotherapeutic 
agent induction of 50% cell death. For the Chou-Talay 
analyses of combination we examined PC3 and DU145 
cells. Importantly, both cell lines are sensitive to selinexor 
(IC50 values for selinexor 380 and 105 nM for PC3 and 
DU145 cells, respectively) and DTX (7.2 and 15.2 nM 
for PC3 and DU145 cells, respectively). Treatments with 
DTX and selinexor in combination in CRPC cell lines 
was synergistic, additive or competitive depending on the 
concentrations used and the cell line studied.
In Figure 5 we show the PC3 (A) and DU145 
(B) synergy heat map for combination indices (CIs) 
calculated by Chou-Talay method. This Figure shows 
that the combination is synergistic at IC20 values for both 
compounds with more points of synergy observed in PC3 
cells than in DU145 cells. In order to calculate the changes 
of IC50 values for DTX in our cell systems we used the 
IC20 values of selinexor or KPT-251 for single cell lines 
and growing doses of DTX. (Figure 5C–5E) confirms that 
administration of SINE compounds sensitizes tumor cells 
to DTX sensitively reducing IC50 values for this anticancer 
agent.
SINE compounds have significant synergistic 
effects in docetaxel-resistant prostate cancer cell 
derivatives restoring DTX sensitivity (Figure 5F–5H): 
co-administration with 50 nM selinexor corresponding to 
IC20 value for PC3DTXR reduced IC50 value calculated 
for docetaxel from 225 nM to 47 nM, a 5-fold reduction. 
Similarly, co-administration of 125 nM KPT-251 (IC20 
value [23]) reduced the IC50 of DTX 2-fold in the same 
cells (IC50 = 3.7 nM). The decrement observed in 22rv1 
was of about 10-fold (44 nM vs 7 nM for selinexor and 6.2 
nM for KPT-251) whereas the reduction of IC50 in DU145 
DTXR was about 6 fold (78 nM vs 12 nM for selinexor 
and 25 nM for KPT-251).
XPO1 inhibitors increased DNA damage when 
used with DTX
In order to demonstrate that selinexor increased 
DNA damage and slowed down DNA repair when used 
in combination with DTX, we evaluated the changes in 
the γH2AX expression by ELISA in PC3 DTXS and PC3 
DTXR cells. This analysis levels revealed that DTX-
induced DNA damage signals (such as γH2AX) could 
not promote complete DNA damage repair in both DTX 
sensitive and resistant cells after pre-treatment with 
selinexor (Figure 6A). Indeed, we observed, a complete 
return to baseline levels of γH2AX at 24 and 48 hours 
in single agent DTX treatment but nor when DTX 
was combined with selinexor. In Figure 6B we show 
immunocytochemical pictures performed on DU145 
DTXR and 22rv1 DTXR cell strains demonstrating that 
in DTXR treated DU145 and 22rv1 cells γH2AX staining 
was significantly increased up to time 8 (T8) and later. 
When we considered combined treatments, γH2AX levels 
reached maximal values at T8-T16 in DU145DTXR 
cells and at T16-T24 in 22rv1DTXR. Some mitosis of 
culture treated with DTX and selinexor in combination 
are strongly γH2AX positive. These mitosis result also 
aberrant. Next we evaluated the expression changes 
in Foxo3a, Chk1 and Chk2 after KPT330 (380 nM) 
administration focusing our attention on PC3 DTXS 
cells (Figure 6C). We observed that 380 nM selinexor 
increased steady state levels of FOXO3 and this could be 
due to p-AMPK down-modulation. This effect was time 
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Figure 6: XPO1 inhibitors increased DNA damage when used with docetaxel. (A) Enzymatic determination of γH2AX histone 
expression in PC3DTXS and PC3DTXR (a Time course experiment). γH2AX expression levels were considered as fold increase vs Time 0 
(T0). (B) immunocytochemical eveluation of gH2AX expression in DU145DTXR and 22rv1DTXR cells treated with 80 nM and 40 nM DTX, 
respectively. (C) Western blot analysis for the expression of DNA repair signaling proteins (ATM/pATM; Foxo3a/pFoxo3a; Chk1/p-Chk1 and 
Chk2/p-Chk2) and bIII tubulin in PC3DTXS cells treated with 380 nM selinexor. (D) Combination treatment: western blot analysis for the 
expression of markers for cell cycle (p21, p27, cyclin D1 and cyclin A2) and apoptosis (bcl2, bim, bax). Induction of caspase 3 activation/cleavage. 
(E) Immunocytochemical evaluation for Foxo3a expression and cytological localization in PC3DTXR cells in CTRL, KPT330 (380 nM), DTX 
(200 nM) and combination showing increase of Foxo3a in the nucleus of DTX plus Selinexor treated cells. (F) Immunocytochemical evaluation 
for β-catenin expression and cytological localization in 22rv1DTXR cells in CTRL, KPT330 (380 nM), DTX (200 nM) and combination showing 
a sensitive decrease of β-catenin in the nucleus of DTX plus Selinexor treated cells. (G) Immunocytochemical evaluation for c-myc expression 
and cytological localization in 22rv1DTXR cells in CTRL, KPT330 (380 nM), DTX (200 nM) and combination showing a sensitive decrease of 
c-myc in the nucleus of DTX plus Selinexor treated cells. (H) PARP cleavage in single and combined treatments indicating increased apoptosis 
and unrepaired DNA after co-administration of KPT330 and DTX. (I) DNA ladder confirming increased DNA fragmentation in the combined 
treatment. (J) Apoptosis evaluation by FACS in DTXS and DTXR cells. Each lane was loaded with 100 μg of proteins.
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dependent and maximal from 12-24 hours (Figure 6C). 
Selinexor was able also to reduce total and phosphorylated 
levels of Chk1/2 as well as reduce βIII tubulin in the 
presence of significant levels of α-tubulin, the major target 
of DTX. Combination treatments were able to modulate 
several proteins involved in the regulation of cell cycle 
(p21, p27, cyclin D1 and cyclin A2) and apoptosis (bcl2, 
bim, bax) inducing caspase 3 cleavage (Figure 6D). In 
Figure 6E we show immunocytochemical evaluation of 
the increase of Foxo3a after DTX and combined DTX 
plus selinexor treatment. Foxo3a appears to be increased 
mainly in the nucleus of DTX plus selinexor treated 
cells. Similarly we observed by immuno-cytochemistry 
that total and nuclear β-catenin (22rv1DTXR, Figure 
6F) expression levels were significantly reduced in 
single DTX or selinexor administration but mainly in 
combined treatments. Cyclin D1 (DU145DTXR, Figure 
6G) levels were increased in the nucleus of DTX treated 
cells but abrogated after selinexor administration alone 
or in combination with DTX. In addition, we observed 
that DTX-induced PARP1 cleavage was increased after 
combination with selinexor (Figure 6H) as result of a 
reduced or slowed down selinexor-inhibited DNA damage 
repair, as previously reported (reference: Ranganathan et 
al 2016). This finding is associated with increased DNA 
fragmentation (DNA laddering, Figure 6I) and apoptosis 
(Figure 6J). In Figure 6H we show also the effects of 
KPT251.
In vivo anti-tumor effect of SINE compounds in 
combination with DTX
To determine the effects of selinexor or KPT-251 
administration on DTX sensitivity in vivo we evaluated 
two SINE compounds (selinexor and KPT-251) in 
combination with DTX in PC3, DU145, 22rv1 cell 
lines, and in DTX resistant PC3 DTXR. The cells were 
subcutaneously injected in athymic male nude mice. In 
order to reduce the probability of biases due to differences 
in tumor engraftment we analyzed the tumor progression 
the parameter “Time to Progression (TTP)”, defined as the 
time (days) necessary to double the tumor volume for each 
tumor, comparing differences of TTP by Kaplan Meyer 
distribution. Xenografted mice were randomly assigned to 
receive therapeutic doses of selinexor, KPT-251 or DTX 
and combinations as described in Materials and methods.
We demonstrate that combination between selinexor 
and DTX (Tables 1 and 2) significantly increased the 
efficacy of single treatments evaluated by tumor weight 
reductions measured at the end of drug administration 
in PC3, DU145 and 22rv1. Selinexor restored also 
the sensitivity to DTX of PC3 DTXR (Table 2). The 
calculation of combination indices revealed that the 
combination involving selinexor and DTX significantly 
increased the efficacy of single treatments evaluated as 
tumor weight reductions with synergistic effects both in 
PC3 DTXR (CI=0.64) and 22rv1 (CI=0.50) xenografts 
and additive effects in PC3 (CI=0.95) and DU145 
(CI=1.12) xenografts. The number of tumors in which 
progression was: (i) 10/10 in the animal groups of CTRL 
and in those treated with selinexor, KPT-251 and DTX, 
and 7/10 (selinexor + DTX) and 8/10 (KPT-251 + DTX) 
in PC3 tumors; (ii) 10/10 in the groups of CTRL and in 
those treated with DTX, selinexor, KPT-251 and in the 
combination KPT-251 + DTX and 6/12 in the group 
treated with selinexor + DTX in DU145 tumors; (iii) 10/10 
in the groups of CTRL and in those treated with DTX, 
selinexor and KPT251, whereas progression was observed 
in 6/10 in the group of animals treated with selinexor + 
DTX and 8/10 in that treated with KPT-251 and DTX in 
22rv1 tumors.
In Figure 7 we show the Kaplan Meyer graphic 
representation of the Time to Progression calculated in the 
single animal groups whereas the calculation of Hazard 
ratios and statistics were enclosed in the Table 3. To 
explore cellular mechanisms that could account for the 
anti-tumor effects we assessed immuno-histochemically 
the tumor cells proliferation (Ki67); apoptosis (TUNEL 
and cleaved-caspase 3) and angiogenesis modification 
(mouse CD31). Data are summarized in Tables 1 and 2 
whereas some pictures of treated and untreated tumors are 
shown in Figure 8).
Immunohistochemical analyses show that combined 
treatment shrinks tumors and exposition of blood vessels, 
significantly decreased the percentage of Ki67 positive 
cells when compared to controls or single drug treatments 
suggesting reduced cell proliferation. (Figure 8A, 
Tables 1 and 2). Increased apoptosis, detected by TACS 
BlueLabel-based TUNEL kit assay was also observed 
(Tables 1 and 2) and was higher in combination treatments 
when compared to single administrations. In particular 
in DU145 xenografts, selinexor alone decreased Ki67 
expression by 68% whereas apoptosis increased by 4 
folds and decreased micro vessel density by 64% (Table 
2). DTX decreased Ki67 by 66% expression, increased 
apoptosis by about 2-folds and decreased micro vessel 
density to about 44%. The combination of selinexor 
plus DTX increased antiproliferative activity reducing 
Ki67 expression by 77% and micro vessel density by 
88%; whereas, it increased apoptosis by about 4 folds. 
The same analyses performed on PC3 and 22rv1 shows 
similar results with different efficacy (Table 1). We also 
analyzed the drug effects on the PC3 DTXR model (Table 
2). These analyses demonstrate that selinexor alone 
decreased Ki67 by 44% whereas apoptosis increased by 
12 times and decreased micro vessel density by 38%. 
DTX shows similar Ki67 expression, and micro vessel 
density. The combination of selinexor plus DTX restored 
the antiproliferative activity, reducing Ki67 expression 
and micro vessel density by 84% whereas, it increased 
apoptosis by 3 times. In addition we observed that total 
expression of XPO1 was also decreased in combined 
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treatments (Figure 8A) as result of the possible DTX-
mediated nuclear accumulation (our in vitro data, see 
above) and selinexor-mediated XPO1 degradation. Next 
we demonstrated increased expression of Foxo3a in 
xenograft tissue of mice receiving DTX, The localization 
was both nuclear and cytoplasmatic. Nuclear expression of 
Foxo3a was increased in selinexor treated tumors whereas 
a reduced nuclear and cytoplasmatic expression of 
Foxo3a was observed in the combined treatment as result 
of a probable increase in Foxo3a degradation. In Figure 
8A we show the IHC pictures obtained in PC3DTXS 
xenografts. A similar behavior was observed for β-catenin 
and cyclin D1 expression after combination treatment 
selinexor and DTX due to increased protein degradation as 
shown in Figure 8B in 22rv1DTXS xenograft. Increased 
caspase 3 expression was also demonstrated in combined 
administration respect to those observed in controls and 
single treatment as shown in Figure 8C in DU145DTXS 
xenograft. These results indicate the combination had a 
greater impact on tumor proliferation and apoptosis then 
single agents.
DISCUSSION
Paclitaxel (PTX), an alkaloid that targets 
microtubules, and its synthetic analogues (i.e. 
docetaxel, DTX) are anticancer drugs validated against 
several human solid tumors. This family of compounds 
Table 1: Antitumor activity of DTX alone or in combination with KPT330 or KPT251 in PC3 and 22rv1 xenografts
Cell 
line
Drug Weight of mice 
(gr +/- SE)
Tumor weight (mg 
+/- SE)
TTP (days +/_ SE) Vessel count (+/- 
SE)
Ki67 (% +/- SE) Apoptosis (% 
+/- SE)
PC3 Vehicle 25,8 ± 0.6 880 ± 140 9.0 ± 1,0 23.2± 2.3 55.5 ± 3.5 < 2
DTX 26.0 ± 0.4 627 ± 172 13.8 ± 1,5 11.5 ± 0.5 34.5 ± 2.5 8.5 ± 1.0
KPT-330 23.8 ± 0.5 560± 94 14.4 ± 0.5 6.4 ± 0.5 25.0 ± 1.0 5.0 ± 0.5
KPT-251 24.5 ± 0.3 666± 94 12.2 ± 0.6 12.0 ± 0.5 30.0 ± 2.0 2.5 ± 0.5
DTX + KPT-330 24.5 ± 0.3 279 ± 59 22.2 ± 0.8 1.3 ± 0.5 10.0 ± 1.5 34.5 ± 3.5
DTX + KPT-251 24.8± 0.6 355± 41 18.9 ± 0.7 4.7 ± 0.5 20.0 ± 1.0 17.0 ± 1.5
22rv1 Vehicle 26.5 ± 0.3 1045 ± 212 10.0 ± 1.5 30.5 ± 2.5 44.0 ± 3.0 < 2
DTX 24.5 ± 0.4 709 ± 145 13.5 ± 1.0 20.0 ± 2.0 35.5 ± 2.0 10.0 ± 0.5
KPT-330 24.0 ± 0.4 527 ± 72 17.0 ± 1.5 8.0 ± 0.5 24.5 ± 2.5 8.5 ± 1.1
KPT-251 23.8 ± 0.55 615±55 15.0 ± 1.0 14.5 ± 0.5 32.0 ± 1.5 < 2
DTX + KPT-330 24.5 ± 0.3 200± 88 22.5 ± 2.0 5.0 ± 0.5 10.5 ± 2.0 44.5 ± 0.5
DTX + KP-T251 25.5 ± 0.3 279 ± 68 20.5 ± 1.5 10.0 ± 0.5 15.5 ± 1.5 30.5 ± 3.5
Table 2: Antitumor activity of DTX alone or in combination with KPT330 or KPT251 in DU145 and PC3DTXR 
xenografts
Cell line Drug Weight of mice (gr 
+/- SE)
Tumor weight (mg 
+/- SE)
TTP (days +/_ 
SE)
Vessel count 
(+/- SE)
Ki67 (% +/- 
SE)
Apoptosis (% 
+/- SE)
DU145 Vehicle 24.5 ± 0.5 798 ± 210 12.6 ± 3.3 24.9 ± 2.4 36.5 ± 3.5 <2
DTX 25.3 ± 0.5 331 ± 86 17.6 ± 2.1 11.5 ± 1.5 16.4 ± 2.5 8.5 ± 1.5
KPT-330 23.8 ± 0.5 477 ± 145 16.4 ± 2.6 6.8 ± 1.2 22.0 ± 3.0 4.0 ±1.0
KPT-251 21.5 ± 1.0 360± 82 15.6 ± 3.2 7.0 ± 0.5 16.5 ± 1.8 7.5 ± 0.5
DTX + KPT-330 21.5 ± 0.5 178 ± 52 22.6 ± 4.1 4,8 ± 0.2 11.8 ± 2.8 19.5 ± 2.5
DTX + KPT-251 21.0± 0.5 224 ± 67 21.6 ± 3.5 3.0 ± 0.1 9.5 ± 0.5 24.5 ± 2.0
PC3DTXR Vehicle 25.0 ± 1.0 1150± 192 8.0 ± 1.0 35.5 ± 3.0 50.0 ± 3.0 < 2
DTX 25.3 ± 0.5 1227 ± 270 8.5 ± 2.0 38.0 ± 2.0 54.5 ± 2.5 <2
KPT-330 24.0 ± 0.5 775 ± 110 13.0 ± 1.5 16.0 ± 0.5 28.0 ± 1.5 12.0 ± 2.5
KPT-251 22.0 ± 1.0 825 ± 120 11.0 ± 1.0 22.0 ± 2.5 35.0 ± 4.0 8.5 ± 1.0
DTX + KPT-330 22.5 ± 0.5 450 ± 50 17.5 ± 2.0 5,5 ± 0.5 8.0 ± 1.0 38.0 ± 5.0
DTX + KPT-251 21.0± 1.0 545± 88 15.5 ± 1.5 8.0 ± 0.5 13.0 ± 2.0 21.0 ± 3.0
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alters and disrupts mitosis, cell motility, and the cell 
proliferation. DTX-resistant (DTXR) cancers highlight 
the rapid onset of multiple cross-resistance and the 
high percentage of failures even in therapies that 
involve drug combinations. Indeed, drug resistance is 
the most important obstacle for treatment of cancer, 
including CRPC. Several molecular mechanisms have 
been identified and are related to increased activation 
of pathways involved in DNA damage repair and cell 
survival. An important role is played by increased 
expression and/or activity of multi-drug resistance 
proteins such as ABCB1 [60, 61]. In our study, we 
demonstrated the possibility that acquired DTXR may 
be overcome by a combinatorial therapy including 
SINE compounds (XPO1 inhibitors) selinexor (KPT-
330) or KPT-251, with the DTX. CRPC drug-sensitive 
cell lines with their drug-resistant strains were used 
in this study. Functionally, DTX interferes with 
microtubule assemblage. It has been demonstrated 
that paclitaxel resistant PC3 cells show decreased 
expression of acetylated α-tubulin and the cell cycle 
regulator p21, and increased expression of βIII tubulin, 
histone deacetylase 6 (HDAC6), and the anti-apoptotic 
protein Bcl2. In our cell models α-tubulin was lower 
cells whereas βIII tubulin and HDAC6 were higher in 
resistant cells when compared with levels observed 
in parental cells. Similarly, these proteins were 
modulated during the treatment with DTX in sensitive 
cells from short term to long term culture (data not 
shown). DTX-mediated microtubule rearrangement 
alters cell division resulting in double-strand DNA 
breaks and subsequent apoptotic cell death. It has been 
widely demonstrated that metastatic CRPC can have 
deep genomic aberrations that interfere with DNA 
Figure 7: In vivo experiments. Kaplan-Meier estimates for rates of progression in 22rv1 PC3, DU145 and PC3DTXR subcutaneous 
tumors.
Oncotarget111238www.impactjournals.com/oncotarget
repair [62, 63]. In addition, several tumor suppressor 
proteins (TSP) and growth regulatory proteins (GRP) 
are mislocalized in cancer cells by overexpression and 
activity of XPO-1 [15–31]. Nuclear and cytoplasmic 
expression of XPO-1 is elevated in prostate tumors 
when compared to normal and hyperplastic tissue [37]. 
Here we demonstrate that XPO-1 is overexpressed in 
DTX resistant CRPC cells and differentially localize 
into the cytoplasm where, several proteins targeted by 
this cargo, are overexpressed. Some of these proteins 
(i.e. survivin) are able to reduce apoptosis whereas 
others increase drug efflux. SINE compounds, which 
inhibit XPO1 activity, have been demonstrated to 
have anticancer effects in models of PCa [23, 37]. In 
this report, we further demonstrate that XPO-1 is a 
potential target for the treatment of aggressive CRPC 
cells in association with DTX. DTX sensitive and DTX 
Resistant cells were also considered for the evaluation 
of in vitro effects. When XPO-1 inhibitors were used 
in combination with DTX, DNA damage signaling was 
increased (increased phospho-H2AX (ϒH2AX) levels), 
but the rate of DNA repair was significantly reduced 
since ϒH2AX levels were maintained for prolonged 
times when compared to DTX alone. This results in 
increased apoptosis and improves the effectiveness 
of DTX. This two-drug combination was also highly 
effective against DTX-resistant CRPC cells. Reduction 
in tumor growth was dose-dependent and associated 
with inhibition of cellular proliferation and activation 
of apoptosis, which correlated with PARP and caspase-3 
cleavage. SINE compounds are potent therapeutic 
tools to treat aggressive/castration resistant PCa cells. 
This appears to be due to the modulation of a multiple 
signaling pathways including time-dependent cyclin 
D1 and survivin decreases in expression. It has been 
demonstrated that cyclin D1 knockdown/decrement 
reduces cell proliferation and increases sensitivity 
to chemotherapy [64] and when sequestered in the 
cytoplasm [65] induces apoptosis. It has been observed 
that selinexor and KPT-251 reduces the export of cyclin 
D1 and P21WAF1 from the nucleus and reduce overall 
expression of cyclin D1 following prolonged exposure. 
Abnormalities in the regulation of cyclin D1 expression 
[66] and cell-cycle inhibitory genes (p21WAF1, 
p16INK4a, and p27KIP1) have been reported in PCa 
[67]. P21WAF1 mainly localizes to the cytoplasm 
where it play an anti-apoptotic role. However, when 
localized in the nucleus, P21WAF1 prevents cell 
cycle progression at the G1 phase. Similarly nuclear 
localization of P27KIP1 enables this regulatory 
function.
High levels of survivin expression are independent 
risk factors for poor prognosis in several cancers and 
the cytoplasmic localization of survivin is particularly 
high in prostate tumors [68], whereas increased nuclear 
expression of survivin is a favorable prognostic factor 
[68]. These observations suggest that nuclear survivin 
is suppressive for tumor growth and further targeting 
the cytoplasmic, antiapoptotic fraction of survivin 
would be an ideal therapeutic avenue. Treatment with 
selinexor or KPT-251 initially promotes survivin nuclear 
localization, but at later time points leads to a reduction 
in its protein levels, which correlates with the timing of 
cellular antitumor effects of these compounds. Together, 
this supports a hypothesis in which XPO-1 inhibition 
leads to a loss of survivin levels, thus inhibiting tumor 
growth and enhanced apoptosis. Reduced expression of 
TUB3, survivin and cyclin D1 conditions tumor cells to 
be more responsive to DTX. In addition the antitumor 
and chemosensitizing effects of SINE compounds 
are sustained by other molecular changes. Foxo3a is 
overexpressed in DTX resistant cells where PI3K/Akt/
mTOR signaling pathways are constitutively activated. 
In this state, Foxo3a is constitutively inactive being in 
the cytoplasm. We observed that KPT-251 and selinexor 
significantly increase nuclear localization of FOXO3a, 
where it becomes active and this is due also by reduced 
activation of PI3K/Akt/mTOR signaling pathways with 
increased nuclear accumulation of Foxo3a. We observed 
also that knockdown of FOXO3a expression using small 
interfering RNA attenuated sensitively the docetaxel 
efficacy (data not shown).
A better understanding of the downstream cellular 
targets of docetaxel and SINE compounds will provide 
information on its mechanism of action and the potential 
of combined treatment in CRPC. Analogous to observed 
effects in lung cancer following cisplatin treatment, 
nuclear accumulation of FOXO3a can be an important 
player for SINE-dependent DTX sensitization in DTXR 
PCa cells. The molecular mechanisms regulating FOXO3a 
cellular localization, however, are complex and largely 
unknown. XPO-1 plays a key role in the shuttling proteins, 
including Foxo3a, from the nucleus to the cytoplasm. The 
phosphorylation of FOXO3a on the Ser7, S253 or Tyr32 
residues can lead to the nuclear localization of FOXO3a. 
Ser7 phosphorylation-deficient mutants seem to be still 
able to activate the expression of Foxo3a target genes [69]. 
In contrast, S253 and Thr32 [70] have been shown to play 
a significant role in the nuclear translocation of Foxo3a. 
It has also been shown that the inhibition of FOXO3a 
phosphorylation at Thr32, observed after Akt inhibition, 
induces FOXO3a nuclear accumulation in lung cancer 
cells with increased expression of the FOXO3a-dependent 
apoptotic protein Bim. DTX and SINE compounds induce 
Foxo3a nuclear accumulation and the activity of apoptotic 
signaling proteins. Moreover, this class of compounds 
has been used in combination studies with standard 
chemotherapies, for example with Topoisomerase II and 
Proteasome Inhibitors [71]. Altogether, this data suggests 
that SINE compounds, in combination with DTX, could be 
used as therapeutic tools for advanced/castration resistant 
prostate tumors.
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Table 3: Statistical analysis performed on Time to Progression Kaplan Meyer curved generated for DTX sensitive 
Pca cells and DTX resistant PC3 cell line
PC3 22rv1 DU145 PC3DTXR
Comparison Hazard 
ratio
Significance Hazard 
ratio
Significance Hazard 
ratio
Significance Hazard 
ratio
Significance
DTX vs vehicle 3.16 P=0.0008 3.36 P=0.0002 6.06 P<0.0001 1.75 P=0.2028 (NS)
KPT330 vs vehicle 7.82 P<0.0001 7.84 P<0.0001 8.49 P<0.0001 5.66 P<0.0001
KPT-330 vs DTX 2.48 P=0.0025 2.33 P=0.0086 1.40 P=0.1954 
(NS)
3.24 P<0.0001
C1 vs vehicle 17.96 P<0.0001 18.52 P<0.0001 19.52 P<0.0001 10.71 P<0.0001
C1 vs DTX 5.70 P<0.0001 5.51 P<0.0001 3.22 P<0.0001 6.12 P<0.0001
C1 vs KPT-330 2.30 P<0.0001 2.36 P=0.0055 2.30 P=0.0012 1.89 P=0.0175
KPT-251 vs vehicle 5.37 P<0.0001 5.20 P<0.0001 6.68 P<0.0001 4.62 P<0.0001
KPT-251 vs DTX 1.70 P=0.1846 (NS) 5.51 P<0.0001 1.10 P=0.7665 
(NS)
3.24 P<0.0001
C2 vs vehicle 13.24 P<0.0001 12.87 P<0.0001 12.36 P<0.0001 8.33 P<0.0001
C2 vs DTX 4,20 P<0.0001 3.83 P<0.0001 2.04 P=0.0884 
(NS)
4.76 P<0.0001
C2 vs KPT-251 2.46 P=0.0036 2.47 P=0.0040 1.85 P=0.1428 
(NS)
1.80 P=0.0116 (NS)
C2 vs C1 1.36 P=0.2554 (NS) 1.44 P=0.2120 (NS) 1.58 P=0.2265 
(NS)
1.37 P=0.5449 (NS)
KPT-251 vs KPT-
330
1.46 P=0.0213 (NS) 1.51 P=0.1877 (NS) 1.27 P=0.7688 
(NS)
1.23 P=0.6290 (NS)
Figure 8: Immunohistochemical analyses of PCa xenograft treated with DTX, KPT330 or combinations in vivo. (A) 
Evaluation of Ki67, XPO1 and Foxo3a in PC3DTXS xenografts. (B) β-catenin and c-myc expression in 22rv1DTXS xenografts. (C) 
Caspase-3 expression in DU145DTXS xenografts.
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MATERIALS AND METHODS
Reagents and drug preparation
All materials for tissue culture were purchased 
from Hyclone (Cramlington, NE, USA). Plasticware was 
obtained from Nunc (Roskilde, Denmark). Antibodies 
including: H3 histone [FL-136, sc-10809], c-myc [9E10, 
sc-40], β-catenin [H-102, sc-7199] p-GSK3β Ser9 
[sc11757], GSK3β [H76, sc-9166], XPO-1 [sc-5595], 
p53 [sc126], p-Akt Ser473 [sc-135651], p-Akt Thr308 
[sc135650], PARP-1 [H-250, sc-7150], DNA-PKCs [H-
163, sc-9051], Chk1 [G-4, sc-8408], Chk2 [A-12, sc-
5278], Topoisomerase 2A [T22C5, sc-65743], ABCB1 
known as Mdr-1 [D-11, sc-55510], HDAC6 [H-300, sc-
11420], βIII tubulin [TU-20, sc-51670], α-tubulin [B-7, 
sc-5286] and acetylated α-tubulin were purchased from 
Santa Cruz (SantaCruz, CA, USA). Antibodies targeting 
Foxo3a [ab37409], p-FOXO3A [ab31109], p(S345)-Chk1 
[ab47318] and p(Thr68-Chk2 [ab32148] were purchased 
from Abcam (Cambridge UK). Antibodies against Cyclin 
D1 [2878], AMPKα [5832], phospho-AMPKα (Thr172) 
[2535] were purchased from Cell Signaling (Danvers, 
MA, USA). The Ki67 antibody (clone MIB-1) was 
purchased from Dako (Dako Italia, Cernusco sul Naviglio 
[MI], Italy). Tunel assay kit [S71003] was purchased from 
Merck KGaA (Darmstadt, Germany). Survivin antibody 
was purchased from Biorbyt.
SINE compounds (KPT-251 and selinexor) were 
provided by Karyopharm Therapeutics Inc., Newton, MA 
whereas DTX was purchased from Selleck Chemicals 
(Aurogene, Rome, Italy). For in vitro studies, all 
compounds were dissolved in DMSO and stored at -20°C 
until use
Cell lines
Three commercial (22rv1, DU145 and PC3) models 
for CRPC were purchased from DSMZ and ATCC. 
PC3, 22rv1 and DU145 DTX-resistant cells (DTXR) 
were selected by cultivating PCa cells in the presence of 
10 nM DTX as previously described [51, 52]. Selected 
clones were pooled and maintained for under continuous 
10 nM docetaxel exposure followed by incremental 
doses of DTX for at least six months. To minimize the 
risk of misidentified and/or contaminated cell lines, 
DNA profiling was periodically carried out in-house to 
authenticate cell cultures. DNA was isolated from cell 
lines using a standard DNA isolation kit. STR profiling 
was performed using GenePrint® 10 System (Promega 
Corporation, Madison, WI). An eight-capillary 3500 
Genetic Analyzer (Applied Biosystems Life Technologies 
Europe BV, Monza, Italy) was used to separate and 
identify alleles using standard procedures. GenePrint® 
10 System allows co-amplification and detection of eight 
human loci required by the guidelines ASN-0002. For 
non-commercial cell lines, the authentication process was 
carried out by comparing STR-fingerprints with those 
published by Adri van Bokhoven and co-workers [53]. In 
addition, cell lines were stocked at very low passages and 
used at <15-20 subcultures.
Growth assays
Cells were seeded at a density of 2 x 104 cells/
mL in 24-well plates. Cells were left to attach and 
grow in 5% FCS DMEM for 24 h. After this time, cells 
were maintained in the appropriate culture conditions. 
Morphological controls were performed every day with an 
inverted phase-contrast photomicroscope (Nikon Diaphot, 
Tokyo, Japan). Cells were trypsinized and resuspended in 
1.0 ml of saline, then counted using a NucleoCounterTM 
NC-100 (automated cell counter systems, Chemotec, 
Gydevang, Denmark). The effect on cell proliferation was 
measured by taking the mean cell number with respect to 
controls over time for the different treatment groups. The 
half-maximal inhibitory concentration (IC50; concentration 
of drug required for a 50% reduction in growth/viability) 
values and combination index (CI) values of the SINE 
molecules when used alone and in combination with 
other drugs were determined by using the Dojindo Cell 
Counting Kit-8 (Dojindo EU GmbH, Munich, Germany).
For drug combination experiments, cell viability 
assays were performed as described above, and the results 
were analyzed for synergistic, additive, and antagonistic 
effects using the CI method developed by Chou and 
Talalay [54].
Cell viability and apoptosis assay
Viable cells were counted using the 
NucleoCounterTM NC-100 (automated cell counter 
systems, Chemotec, Cydevang, DK). Apoptosis was 
evaluated by using Tali® Apoptosis Kit - Annexin V Alexa 
Fluor® 488 & Propidium Iodide-based, (Life Technologies 
Italia, Monza, Italy). Stained cells were then measured on 
a Tali® Image-Based Cytometer. Apoptosis was further 
confirmed by FACS analysis following the instructions of 
the manufacturer.
Western blot
Cytoplasmic and nuclear protein extracts were 
obtained by using the Nuclear/Cytosol Fractionation Kit 
from Biovision Inc. (Milpitas, CA, USA). Cell extracts 
and conditioned media from treated and untreated cells 
were electrophoresed under reducing conditions and 
transferred to nitrocellulose filter (Schleicher and Schuell 
GmbH, Dassel, Germany). Reactive bioluminescent bands 
were visualized by using the detection kit (Supersignal, 
Perbio Science, Tattenhall, UK) using Bio-Rad gel DocTM 
(Bio-Rad Laboratories S.r.l., Milan, Italy).
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Xenograft model
Male CD1 nude mice (Charles River, Milan, Italy) 
were maintained under the guidelines established by the 
University of L’Aquila, Medical School and Science and 
Technology School Board Regulations. Experiments 
on animals have been approved by your local IRB in 
compliance with the Italian government regulation 
n.116 January 27, 1992 for the use of laboratory animals 
which is line with ARRIVE guidelines. All mice received 
subcutaneous flank injections of 1 x 106 PC3, DU145, 
22v1 cells or PC3DTXR. Tumor growth was measured 
bi-weekly with a Vernier caliper (length x width). Tumor 
weight was calculated according to the formula: TW (mg) 
= tumor volume (mm3) = d2 x D/2, where d and D are the 
shortest and longest diameters, respectively. The effects of 
the treatments were examined as previously described [55, 
56]. Animals were sacrificed by carbon dioxide inhalation 
and tumors were subsequently removed surgically. A 
piece of tumor was frozen in liquid nitrogen for protein 
analysis and another piece was fixed in paraformaldehyde 
overnight for immunohistochemical analyses.
Treatments
Mice were treated by oral gavage with either vehicle 
control (Pluronic F-68/PVP-K29/ 32), selinexor or KPT-
251. Groups of 10 animals were considered. Before tumor 
injection, animals were randomized to receive (i) vehicle 
(PBS 1 mL/kg i.p., 2/week and povidone/pluronic F68 
1 mL/kg p.o., 3/week), (ii) selinexor (10 mg/Kg, q 2d × 
3 weeks, po), (iii) docetaxel (i.p. injection of 7.5 mg/kg 
per week), (iv) selinexor (110 mg/Kg, q 2d × 3 weeks, 
po) + DTX (i.p. injection of 7.5 mg/kg per week). KPT-
251, was also tested at 30 mg/kg q2d × 3 weeks, po and 
in the same combinations. Treatments were started when 
tumor volumes reached approximately 80 mm3 (Day 0) 
and were stopped after 28 days. The following parameters 
were used to quantify the antitumor effects upon different 
treatments: (1) tumor volume measured during and at the 
end of experiments, (2) tumor weight measured at the end 
of experiment, (3) complete response (CR) defined as the 
disappearance of the target lesion with respect to baseline, 
(4) tumor progression (TP) defined as an increase of 
greater than 50% of tumor volume with respect to baseline, 
(5) time to progression (TTP). In vivo, combinational 
studies were evaluated by CalcuSyn (Biosoft). For the 
calculation of CI, the values of cell kill for a fixed tumor 
volume were considered (determined by the log cell kill 
(LCK)). LCK was determined as LCKZ (TKC)/(3.3KTd), 
where Td represents the mean control group doubling time 
required to reach a fixed tumor volume, expressed in days, 
whereas T and C are the same values as described above 
[55].
Immunohistochemical analyses
Indirect immunoperoxidase staining of tumor 
xenografts samples was performed on paraffin embedded 
tissue sections (4 μm). Briefly, sections were incubated 
with primary antibodies overnight at 4°C. Next, avidin–
biotin assays were done using the Vectastain Elite kit 
obtained from Vector Laboratories. Mayer’s hematoxylin 
was used as nuclear counterstain. Ki67 labeling index was 
determined by counting 500 cells at 100X and determining 
the percentage of cells staining positively for Ki67. 
Apoptosis was determined by using the TACS TdT in situ 
TACS Blue Label kit (code 4811-30-K; R&D Systems, 
Inc. Minneapolis, MN). Apoptosis was measured as the 
percentage of tunnel positive cells +/- SD measured on 
five random fields (400 X).
Tumor microvessels were counted at ×400 in five 
arbitrarily selected fields and the data were presented as 
number of CD31+ microvessels / ×100 microscopic field 
for each group. The presence of red cells in tumor tissue 
and in blood vessels as well as the presence of micro-
thrombi and bleeding zones was demonstrated by Martius 
yellow-brilliant crystal scarlet blue technique. Tumor 
hemoglobin levels were quantified as described elsewhere 
[41].
Statistical analysis
Continuous variables were summarized as the mean 
and SD or 95% CI for the mean. Statistical comparisons 
between controls and treated groups were established 
by carrying out the ANOVA test or by Student’s t-test 
for unpaired data (for two comparisons). Dichotomous 
variables were summarized by absolute and/or relative 
frequencies. For dichotomous variables, statistical 
comparisons between control and treated groups were 
established by carrying out the exact Fisher’s test. For 
multiple comparisons, the level of significance was 
corrected by multiplying the P value by the number of 
comparisons performed (n) according to the Bonferroni 
correction. Overall survival was determined by Kaplan–
Meier analysis and a Gehan’s generalized Wilcoxon test. 
When more than two survival curves were compared, the 
Logrank test for trend was used. This tests the probability 
that there is a trend in survival scores across the groups. 
All tests were two-sided and were determined by Monte 
Carlo significance. P values <0.05 were considered 
statistically significant. In the figures in which statistical 
analysis was performed, significance is indicated by an 
asterisk. SPSS (statistical analysis software package, IBM 
Corp., Armonk, NY, USA) version 10.0 and StatDirect 
(version. 2.3.3, StatDirect Ltd, Altrincham, Manchester, 
UK) were used for statistical analysis and graphical 
presentation.
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